Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 4/2007

01.04.2007 | Article

Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy

verfasst von: J. Gómez, E. García-Vázquez, R. Baños, M. Canteras, J. Ruiz, V. Baños, J. A. Herrero, M. Valdés

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to evaluate prognostic factors and the influence of different empiric antibiotic therapies on outcome and mortality in a cohort of 100 inpatients with bacteraemia (84 cases nosocomial) caused by methicillin-resistant Staphylococcus aureus (MRSA). Patients were investigated by means of a standard protocol at a 944-bed hospital in the years 2000–2004. Empiric antibiotic therapies included vancomycin (n = 49), teicoplanin (n = 20), linezolid (n = 17), other antibiotics active in vitro (n = 7), and inactive antibiotics (n = 7). Overall mortality was 40% (12% among linezolid-treated patients; 46.3% among glycopeptide-treated patients). In bivariate analyses, the following factors were statistically associated with higher mortality: rapidly fatal underlying disease, altered mental status, metabolic acidosis, and acute severe clinical condition at the onset of bacteraemia; development of complications (septic shock, renal failure, and disseminated intravascular coagulopathy); empiric monotherapy with glycopeptides (vs combination therapy with an aminoglycoside); and inadequate empiric treatment. Empiric therapy with linezolid was associated with lower mortality. In multivariate analysis, risk factors associated with higher mortality included acute severity of illness (OR 7.49; 95%CI 1.19–25.3) and altered mental status (OR 4.83; 95%CI 1.22–19.15) at onset, complications (OR 3.42; 95%CI 1.02–17.46), and inappropriate empiric treatment (OR 7.6; 95%CI 1.87–31.14). In multivariate analysis limited to patients who received empiric therapy with either linezolid (n = 17) or glycopeptides (n = 69), linezolid was associated with greater rates of survival (OR 7.7; 95%CI 1.1–53) and microbiological eradication (OR 11.76; 95%CI 1.46–90.9) but not with fewer complications (OR 0.71; 95%CI 0.16–3.25). In conclusion, the main prognostic factors associated with mortality in patients with MRSA bacteraemia are complications, acute severe clinical condition at onset, and inappropriate empiric treatment. Empiric therapy with linezolid was associated with greater survival and more successful microbiological eradication but did not reduce complications.
Literatur
1.
Zurück zum Zitat Selvey L, Whitby M, Johnson B (2000) Nosocomial methicillin-resistant S. aureus bacteraemia: is it any worse than nosocomial methicillin-sensitive S. aureus bacteraemia? Infect Control Hosp Epidemiol 21:645–648PubMedCrossRef Selvey L, Whitby M, Johnson B (2000) Nosocomial methicillin-resistant S. aureus bacteraemia: is it any worse than nosocomial methicillin-sensitive S. aureus bacteraemia? Infect Control Hosp Epidemiol 21:645–648PubMedCrossRef
2.
Zurück zum Zitat Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N Monen J, Witte W, Grundman H, and the European Antimicrobial Resistance Surveillance System Participants (2004) Methicillin-resistant S. aureus in Europe, 1999–2002. Emerg Infect Dis 10:1627–1634PubMed Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N Monen J, Witte W, Grundman H, and the European Antimicrobial Resistance Surveillance System Participants (2004) Methicillin-resistant S. aureus in Europe, 1999–2002. Emerg Infect Dis 10:1627–1634PubMed
3.
Zurück zum Zitat Oteo J, Cruchaga S, Campos J, Sáez JA, Baquero F, and Spanish Members of the European Antimicrobial Resistance Surveillance System (EARSS) (2002) Resistencia a antibióticos en S. aureus aislados de sangre en 31 hospitales españoles de la Red Europea de Vigilancia de Resistencia a Antibióticos (2000). Med Clin 119:361–365 Oteo J, Cruchaga S, Campos J, Sáez JA, Baquero F, and Spanish Members of the European Antimicrobial Resistance Surveillance System (EARSS) (2002) Resistencia a antibióticos en S. aureus aislados de sangre en 31 hospitales españoles de la Red Europea de Vigilancia de Resistencia a Antibióticos (2000). Med Clin 119:361–365
4.
Zurück zum Zitat Cosgrove SE, Sakoulas G, Perencevich EN, Schawer MJ, Karchmer AW (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible S. aureus bacteraemia: a meta-analysis. Clin Infect Dis 36:53–59PubMedCrossRef Cosgrove SE, Sakoulas G, Perencevich EN, Schawer MJ, Karchmer AW (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible S. aureus bacteraemia: a meta-analysis. Clin Infect Dis 36:53–59PubMedCrossRef
5.
Zurück zum Zitat Soriano A, Martínez JA, Mensa J, Marco F, Almela M, Moreno-Martínez A, Sánchez F, Muñoz I, Jiménez de Anta MT, Soriano E (2000) Pathogenic significance of methicillin resistance for patients with S. aureus bacteraemia. Clin Infect Dis 30:368–373PubMedCrossRef Soriano A, Martínez JA, Mensa J, Marco F, Almela M, Moreno-Martínez A, Sánchez F, Muñoz I, Jiménez de Anta MT, Soriano E (2000) Pathogenic significance of methicillin resistance for patients with S. aureus bacteraemia. Clin Infect Dis 30:368–373PubMedCrossRef
6.
Zurück zum Zitat Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired S. aureus bacteraemia. Clin Infect Dis 36:1418–1423PubMedCrossRef Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired S. aureus bacteraemia. Clin Infect Dis 36:1418–1423PubMedCrossRef
7.
Zurück zum Zitat Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, O’Donnell A, Wagener MM, Yu VL (2003) A prospective multicenter study of S. aureus bacteraemia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 82:322–332PubMedCrossRef Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, O’Donnell A, Wagener MM, Yu VL (2003) A prospective multicenter study of S. aureus bacteraemia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 82:322–332PubMedCrossRef
8.
Zurück zum Zitat Garnes JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140CrossRef Garnes JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140CrossRef
9.
Zurück zum Zitat McCabe WR, Jackson GG (1962) Gram-negative bacteraemia. Etiology and ecology. Arch Intern Med 110:847–855 McCabe WR, Jackson GG (1962) Gram-negative bacteraemia. Etiology and ecology. Arch Intern Med 110:847–855
10.
Zurück zum Zitat Winston DJ, Murphy W, Young LS, Hewitt WL (1980) Piperacillin therapy for serious bacterial infections. Am J Med 69:255–261PubMedCrossRef Winston DJ, Murphy W, Young LS, Hewitt WL (1980) Piperacillin therapy for serious bacterial infections. Am J Med 69:255–261PubMedCrossRef
11.
Zurück zum Zitat Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimødt-Møller N (2002) Treatment and outcome of S. aureus bacteraemia. A prospective study of 278 cases. Arch Intern Med 162:25–32PubMedCrossRef Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimødt-Møller N (2002) Treatment and outcome of S. aureus bacteraemia. A prospective study of 278 cases. Arch Intern Med 162:25–32PubMedCrossRef
12.
Zurück zum Zitat Blot S, Vandewoude K, Hoste E, Colardyn F (2002) Attributable mortality in critically ill patients with bacteraemia involving methicillin-susceptible and methicillin-resistant S. aureus. Arch Intern Med 162:2229–2235PubMedCrossRef Blot S, Vandewoude K, Hoste E, Colardyn F (2002) Attributable mortality in critically ill patients with bacteraemia involving methicillin-susceptible and methicillin-resistant S. aureus. Arch Intern Med 162:2229–2235PubMedCrossRef
13.
Zurück zum Zitat Blot S (2005) MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 33:2127–2128PubMedCrossRef Blot S (2005) MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 33:2127–2128PubMedCrossRef
14.
Zurück zum Zitat Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant S. aureus bacteraemia. J Clin Microbiol 42:2398–2402PubMedCrossRef Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant S. aureus bacteraemia. J Clin Microbiol 42:2398–2402PubMedCrossRef
15.
Zurück zum Zitat Knatib R, Riederer KM, Held M, Aljundi H (1995) Protracted and recurrent methicillin-resistant S. aureus bacteraemia despite defervescence with vancomycin therapy. Scand J Infect Dis 27:529–532 Knatib R, Riederer KM, Held M, Aljundi H (1995) Protracted and recurrent methicillin-resistant S. aureus bacteraemia despite defervescence with vancomycin therapy. Scand J Infect Dis 27:529–532
16.
Zurück zum Zitat Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML (2004) Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate S. aureus. Clin Infect Dis 38:448–451PubMedCrossRef Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML (2004) Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate S. aureus. Clin Infect Dis 38:448–451PubMedCrossRef
17.
Zurück zum Zitat Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388–394PubMedCrossRef Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388–394PubMedCrossRef
18.
Zurück zum Zitat Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188:760–766PubMedCrossRef Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188:760–766PubMedCrossRef
19.
Zurück zum Zitat Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for S. aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:923–929PubMedCrossRef Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for S. aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:923–929PubMedCrossRef
20.
Zurück zum Zitat Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermöhlen O, Krut O, Müller S, Krönke M (2004) Subinhibitory concentrations of linezolid reduce S. aureus virulence factors expression. Antimicrob Agents Chemother 48:546–555PubMedCrossRef Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermöhlen O, Krut O, Müller S, Krönke M (2004) Subinhibitory concentrations of linezolid reduce S. aureus virulence factors expression. Antimicrob Agents Chemother 48:546–555PubMedCrossRef
Metadaten
Titel
Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy
verfasst von
J. Gómez
E. García-Vázquez
R. Baños
M. Canteras
J. Ruiz
V. Baños
J. A. Herrero
M. Valdés
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2007
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0272-x

Weitere Artikel der Ausgabe 4/2007

European Journal of Clinical Microbiology & Infectious Diseases 4/2007 Zur Ausgabe

Announcements

Announcements

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.